Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks

Key Patent Covers Manufacture of Therapeutic Products Containing a High Percentage of T Stem Cell Memory Cells

SAN DIEGO, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent protecting the method of producing genetically modified T cells with a high percentage of stem cell memory T cells (Tscm).

Tscm cells are long-lived, self-renewing and multipotent. These cells have the capacity to reconstitute the entire spectrum of effector and memory T cells subsets and usually survive for decades and potentially for entire lifespans. The wholly-owned patent covers the method of producing genetically modified T cell products that are comprised of 25% or more Tscm cells.

“These additions to our patent portfolio further validate the novel advancements we have made in Tscm-based product candidates,” said Eric Ostertag, M.D., Ph.D., chief executive officer of Poseida. “Our innovative CAR-T product candidates, utilizing a proprietary non-viral delivery method, are comprised of a high percentage of stem cell memory T cells, which we believe are important for safety and efficacy of CAR-T approaches to treat both liquid and solid tumors.”

The Company’s lead product candidate, P-BCMA-101, is an autologous CAR-T therapeutic candidate to treat patients with relapsed/refractory multiple myeloma. This and other product candidates currently in development are comprised of a high percentage of Tscm cells.

The Company has also received a Notice of Allowance on a patent that is part of a broader portfolio protecting its piggyBac® DNA Modification System, a proprietary non-viral DNA delivery method. The Company also received approval for registered trademarks of both “piggyBac” and “Footprint-Free®”, the latter referring to a platform technology designed to allow for gene editing of as little as a single nucleotide in 100% of target cells.

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biotechnology company leveraging proprietary next-generation non-viral, gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. The company is developing a wholly-owned pipeline of autologous and allogeneic CAR-T product candidates, initially focused on the treatment of hematological malignancies and solid tumors. Poseida’s product candidates are designed to address the limitations of other CAR-T therapies, including duration of response, the ability to treat solid tumors and safety concerns.

Contacts:
Marcy Graham
VP, Corporate Affairs
Poseida Therapeutics, Inc.
858-779-3108
mgraham@poseida.com